Ellagic Acid's Protective Effect Against Experimental Obstructive Hepatic Encephalopathy Associated with Jaundice
Ellagic acid showed potential in improving cognitive and locomotor functions in a rat model of hepatic encephalopathy, but further research is needed to confirm its effects in humans.
Where it sits
this study against the rest of the glutathione (gsh) corpusSummary and findings
This study measured the effects of ellagic acid (EA) on cognitive and locomotor performance in a bile duct ligation (BDL)-induced experimental hepatic encephalopathy model in female Wistar rats. EA was administered at a dose of 25 mg/kg via intraperitoneal injection for 14 days. Results indicated that EA improved performance and restored antioxidant status while reducing oxidative stress markers.
Abstract
Abstract Background Obstructive jaundice can progress to hepatic encephalopathy (HE) through systemic toxin accumulation, oxidative stress, and neuroinflammation. Aims This study investigated the neuroprotective and hepatoprotective effects of ellagic acid (EA) in a bile duct ligation (BDL)-induced experimental HE model, focusing on oxidative stress-responsive heme oxygenase-1 (HO-1) alterations. Methods Forty female Wistar rats were divided into Control, Sham, EA, BDL, and BDL + EA groups. EA (25 mg/kg) was administered prophylactically via intraperitoneal (i.p.) injection for 14 days. Cognitive and locomotor performances were assessed using the Novel Object Recognition (NOR) and Open Field tests (OFT). Biochemical analyses evaluated liver enzymes, bilirubin, reduced glutathione (GSH), malondialdehyde (MDA), HO-1, and interleukin-1β (IL-1β) levels in serum, liver, and hippocampal tissues. Results BDL significantly impaired behavioral performance, increased liver enzymes, MDA, HO-1, and IL-1β levels, and depleted GSH levels in all examined tissues (p < 0.05). EA administration significantly improved cognitive and locomotor outcomes, restored antioxidant status, and reduced lipid peroxidation. Furthermore, EA attenuated HO-1 and IL-1β elevations, suggesting attenuation of oxidative stress and inflammatory responses. Conclusions EA exerts hepatoprotective and neuroprotective effects by restoring oxidant-antioxidant balance and suppressing neuroinflammatory responses, suggesting its potential as a therapeutic approach for liver-brain axis dysfunction.
Background
This paper addresses the progression of obstructive jaundice to hepatic encephalopathy, which is associated with systemic toxin accumulation and oxidative stress. Prior knowledge indicates that oxidative stress and neuroinflammation are critical factors in this progression. The study is significant as it explores the neuroprotective and hepatoprotective effects of ellagic acid, a compound not extensively studied in this context.
Methods
The study utilized a bile duct ligation (BDL) model in 40 female Wistar rats, divided into Control, Sham, EA, BDL, and BDL + EA groups. Ellagic acid was administered at a dose of 25 mg/kg via intraperitoneal injection for 14 days. Primary outcome measures included cognitive and locomotor performances assessed through the Novel Object Recognition and Open Field tests, while secondary measures included biochemical analyses of liver enzymes, bilirubin, GSH, MDA, HO-1, and IL-1β levels.
Results
BDL significantly impaired behavioral performance and increased liver enzymes, MDA, HO-1, and IL-1β levels, along with depleting GSH levels in all examined tissues (p<0.05). EA administration significantly improved cognitive and locomotor outcomes, restored antioxidant status, and reduced lipid peroxidation. EA also attenuated elevations of HO-1 and IL-1β, indicating a reduction in oxidative stress and inflammatory responses.
Interpretation
The findings suggest that ellagic acid has potential neuroprotective and hepatoprotective effects, aligning with previous literature on oxidative stress mitigation. However, the clinical significance of these effects remains uncertain, particularly given the small sample size and the use of an animal model. The study's conclusions may not be directly applicable to human patients due to these limitations.
Key findings
- p<0.05 for increased liver enzymes, MDA, HO-1, and IL-1β levels in BDL group compared to control.
- GSH levels were depleted in all examined tissues in the BDL group (p<0.05).
- EA administration significantly improved cognitive and locomotor outcomes.
- EA restored antioxidant status and reduced lipid peroxidation.
- EA attenuated HO-1 and IL-1β elevations.
Limitations
- rodent model may not fully translate to humans
- sample size of 40 rats may limit generalizability
- short duration of 14 days may not capture long-term effects
- no human data provided